Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by ...

Discover how Akero Therapeutics' EFX outshines competitors in MASH treatment, with groundbreaking results and strong ...

Corebridge Financial Inc. lowered its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 7.0% in ...

Insiders have lately been showing their love for these three biotech stocks, two tech stocks, and a utility stock with huge ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money ...

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report)’s stock price gapped up before the market opened on Friday after an insider bought additional shares in the company. The stock had previously ...

This article summarizes the most significant insider buys and sells from Thursday, March 27, 2025, for US stocks.

New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial ...

Drug development is coming back in vogue and this fund’s ‘full life cycle’ approach means it’s ready to capture the gains ...

NEW YORK CITY, NY / ACCESS Newswire / March 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity ...

Akero Therapeutics may not have adequate data for accelerated approval of its MASH drug, despite showing it may reverse cirrhosis in patients with severe liver disease.